ORCID as entered in ROS
https://orcid.org/0000-0002-9029-6663
Select Publications
Journal articles
, 2007, 'Transfer of allograft specific tolerance requires CD4(+)CD25(+)T cells but not interleukin-4 or transforming growth factor-beta and cannot induce tolerance to linked antigens', Transplantation, 83, pp. 1075 - 1084
, 2007, 'Transplant tolerance associated with a Th1 response and not broken by IL-4, IL-5, and TGF-beta blockade or Th1 cytokine administration', Transplantation, 83, pp. 764 - 773
, 2006, 'Developing strategies to manage neutralising antibodies - preliminary results from the RENeu study', Multiple Sclerosis, 12, pp. S203 - S204
, 2006, 'Relationship between stress and relapse in multiple sclerosis: part II Direct and indirect relationships.', Multiple Sclerosis, 12, pp. 465 - 475
, 2006, 'Relationship between stress and relapse in multiple sclerosis:Part 1. Important features', Multiple Sclerosis, 12, pp. 453 - 464
, 2006, 'The cellular basis of cardiac allograft rejection. IX. Ratio of naïve CD4+CD25+ T cells / CD4+CD25− T cells determines rejection or tolerance', Transplant Immunology, 15, pp. 311 - 318
, 2005, 'Posttransplant interleukin-4 treatment converts rat liver allograft tolerance to rejection', Transplantation, 79, pp. 1116 - 1120
, 2004, 'Tissue plasminogen activator (tPA) in acute ischaemic stroke: Time for collegiate communication and consensus', Medical Journal of Australia, 180, pp. 634 - 636, http://dx.doi.org/10.5694/j.1326-5377.2004.tb06127.x
, 2004, 'POST-TRANSPLANT IL-4 TREATMENT CONVERTS RAT LIVER ALLOGRAFT TOLERANCE TO REJECTION', Transplantation, 78, pp. 153 - 153, http://dx.doi.org/10.1097/00007890-200407271-00404
, 2002, 'Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords', Journal of Immunology, 168, pp. 4293 - 4300, http://dx.doi.org/10.4049/jimmunol.168.9.4293
, 2001, 'Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?', Journal of Clinical Neuroscience, 8, pp. 378 - 379, http://dx.doi.org/10.1054/jocn.2001.0911
, 2001, 'IL-4 Therapy Prevents the development of proteinuria in active Heymann Nephritis by inhibition of Tc1 cells', Journal of Immunology, 167, pp. 3725 - 3733
, 2001, 'Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis', International Immunopharmacology, 1, pp. 1709 - 1723
, 2001, 'Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAB therapy with a preferential effect on Th1 cells that is augmented by IL-4', International Immunology, 13, pp. 1109 - 1120
, 1999, 'Corticosteroids in Autoimmunity', Australian Prescriber, pp. 15 - 18
, 1998, 'Corticosteroids in autoimmune diseases.', Australian Prescriber, pp. 9 - 11
, 1997, 'Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial', Neurology, 49, pp. 351 - 357, http://dx.doi.org/10.1212/WNL.49.2.351
, 1996, 'Tumor necrosis factor α and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon γ stimulation', Journal of Neuroimmunology, 71, pp. 65 - 71, http://dx.doi.org/10.1016/S0165-5728(96)00131-2
, 1996, 'Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis', Annals of Neurology, 39, pp. 6 - 16, http://dx.doi.org/10.1002/ana.410390104
, 1996, 'A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis', Multiple Sclerosis, 1, pp. 339 - 342, http://dx.doi.org/10.1177/135245859600100611
, 1995, 'Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS.', Journal of Neuroimmunology, 56-63, pp. 15 - 15, http://dx.doi.org/10.1016/0165-5728(95)98902-n
, 1994, 'Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis', Neurology, 44, pp. 413 - 419, http://dx.doi.org/10.1212/wnl.44.3_part_1.413
, 1994, 'Repeated treatment with chimeric anti‐CD4 antibody in multiple sclerosis', Annals of Neurology, 36, pp. 183 - 189, http://dx.doi.org/10.1002/ana.410360210
, 1994, 'Transfer of experimental allergic neuritis by intra neural injection of sensitized lymphocytes', Journal of the Neurological Sciences, 123, pp. 162 - 172, http://dx.doi.org/10.1016/0022-510X(94)90219-4
, 1993, 'Diverse T cell receptor Vβ gene usage in the central nervous system in experimental allergic encephalomyelitis', Journal of Immunology, 150, pp. 4085 - 4092
, 1993, 'From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis.', Immunology Series, 59, pp. 253 - 260
, 1991, 'A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis', Proceedings of the National Academy of Sciences of the United States of America, 88, pp. 9633 - 9637
, 1991, 'Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides', Blood, 77, pp. 20 - 30, http://dx.doi.org/10.1182/blood.v77.1.20.20
, 1990, 'Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy', Journal of Neurology Neurosurgery and Psychiatry, 53, pp. 327 - 330, http://dx.doi.org/10.1136/jnnp.53.4.327
, 1989, 'Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins', Proceedings of the National Academy of Sciences of the United States of America, 86, pp. 9470 - 9474, http://dx.doi.org/10.1073/pnas.86.23.9470
Conference Papers
, 2024, '3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis', in Young Investigators Session Abstracts, BMJ Publishing Group Ltd, pp. A2.1 - A2, presented at
, 2024, '3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis', in Poster Abstracts, BMJ Publishing Group Ltd, pp. A43.1 - A43, presented at
, 2024, '3149 Real-world Australian experience with Ofatumumab in the MSBase registry', in Poster Abstracts, BMJ Publishing Group Ltd, pp. A45.3 - A46, presented at
, 2023, 'Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018)', in Neurology, Ovid Technologies (Wolters Kluwer Health), http://dx.doi.org/10.1212/wnl.0000000000202977
, 2023, 'Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study', in NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, MA, Boston, presented at
, 2023, '2723 Secondary progressive multiple sclerosis patients in Australia treated with siponimod; novel real-world evidence from the MSGo digital support program', in Poster Abstract, BMJ Publishing Group Ltd, pp. A41.2 - A41, presented at
, 2023, 'Novel Real World Evidence from MSGo, a Digital Support Program for Secondary Progressive Multiple Sclerosis Patients in Australia using Siponimod', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. NP44 - NP46
, 2022, 'Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 5 - 6, presented at
, 2022, 'Confirmed disability progression as a marker of permanent disability in multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 8 - 8, presented at
, 2022, 'Confirmed disability progression as a marker of permanent disability in multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 8 - 8, presented at
, 2022, 'Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 6 - 7, presented at
, 2022, 'Time to relapse after switching to cladribine is predicted by relapse during the washout period', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 11 - 11, presented at
, 2022, '2258 Novel generation of real-world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in Australia', in Abstracts, BMJ Publishing Group Ltd, pp. A25.1 - A25, presented at
, 2022, '2327 Latitude, UVR and multiple sclerosis severity', in Abstracts, BMJ Publishing Group Ltd, pp. A11.3 - A12, presented at
, 2022, 'Cladribine: a multicentre, LOng-term efficacy and Biomarker Australian Study (CLOBAS)', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 26 - 26
, 2022, 'Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 5 - 6
, 2022, 'Disease reactivation after cessation of diseasemodifying therapy in relapsing-remitting multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 6 - 7
, 2022, 'Time to relapse after switching to cladribine is predicted by relapse during the washout period', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 11 - 11
, 2022, 'Variability of the response to immunotherapy among sub-groups of patients with multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 7 - 7
, 2021, '004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis', in Oral abstracts, BMJ Publishing Group Ltd, pp. A2.1 - A2, presented at
Filter by type
https://orcid.org/0000-0002-9029-6663